Thu May 22 11:45:37 UTC 2025: **Summary:**
A clinical trial in India, funded by ICMR and led by CMC Vellore, has successfully demonstrated the safe and cost-effective production and infusion of CAR-T cell therapy for cancer treatment within a hospital setting. This “point-of-care” (PoC) manufacturing method significantly reduces costs by approximately 90% compared to global averages. The trial showed promising results with high remission rates in patients with acute lymphoblastic leukemia and large B-cell lymphoma who had previously failed other treatments. The therapy was also well-tolerated with minimal side effects. Researchers believe this model can be replicated in other tertiary healthcare facilities in India, making advanced cancer treatment more accessible and affordable.
**News Article:**
**Indian Hospital Achieves Breakthrough in Affordable Cancer Therapy**
**Vellore, India – May 22, 2025** – A landmark clinical trial conducted by CMC Vellore and funded by the Indian Council of Medical Research (ICMR) has proven the feasibility and efficacy of producing CAR-T cell therapy, a cutting-edge cancer treatment, directly within a hospital setting, drastically reducing costs for patients.
CAR-T cell therapy involves engineering a patient’s own immune cells (T cells) to recognize and attack cancer cells. Traditionally, this process is outsourced to large commercial companies, resulting in high costs and logistical challenges. The CMC Vellore trial successfully implemented “point-of-care” (PoC) manufacturing, where CAR-T cells are produced on-site.
The study, published in the journal *Molecular Therapy*, treated ten patients with acute leukemia and lymphoma who had exhausted all other treatment options. The results were highly encouraging, with a 100% remission rate in acute lymphoblastic leukemia patients and a 50% remission rate in large B-cell lymphoma patients. Overall, eight of the ten patients remained cancer-free after a median follow-up of 15 months. Furthermore, the therapy was found to be safe and well-tolerated with minimal side effects.
“This trial redefines how cancer therapy can be delivered – efficiently, affordably, and close to patients,” stated Dr. Vikram Mathews, Director of CMC Vellore and principal author of the study. He emphasized that the PoC model reduces the cost of therapy by nearly 90% compared to global averages. The production time for CAR-T cells was just nine days in the in-hospital setting, and the use of fresh, unfrozen products further contributed to better outcomes.
The success of this trial signifies a major step forward in making advanced cancer treatments more accessible to patients in India and potentially around the world. Dr. Mathews believes that this model can be easily replicated in most tertiary healthcare facilities in the country, paving the way for a new era of affordable and effective cancer care. India is now at the forefront of developing next-generation, in-house biotherapies with global relevance.
First Piper 